Artrya Limited · ASX:AYA
Artrya — H1 FY2022 Earnings Presentation
20 slides from Artrya's earnings presentation, Feb 21, 2022
Slide 1: Artrya FY22 Half Year Results Presentation
For personal use only Artrya FY22 Half Year Results Presentation ASX: AYA
Slide 2: Important notice and disclaimer
Important notice and disclaimer from, this presentation including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. The IMPORTANT NOTICE Company has not carried out due diligence investigations in connection with the p
Slide 3: Coronary Artery Disease is a leading cause of death globally
126 Coronary Artery Disease is a million leading cause of death globally. For personal use only people with significant heart disease1 $219 Every 13 billion minutes heart disease costs Someone in the United States Australia dies of a each year4 heart attack3 One third 9 million of deaths globally CA
Slide 4: Vulnerable plaque
unstable soft plaque that ruptures For personal use only Vulnerable Plaque. Build up of Plaque 4
Slide 5: Artrya's purpose is to save lives
Artrya’s Purpose is to save lives, creating social & economic value. We will do this by: For personal use only Using gold standard Addressing imaging modality CCTA Partnering The global problem of heart with globally recognised health research partners Piloting in Australia before launch in the US a
Slide 6: Progress in months since IPO
Progress in 3 months since IPO For personal use only 26 November 2021 December 2021 December 2021 13 January 2022 February 2022 Artrya IPO Salix Coronary Negotiation Appointment of US team Flow completed commenced with Dr Jacque Sokolov, expanded to full on schedule leading UK NHS Chair Scientific &
Slide 7: US – market entry
US – market entry For personal use only Full time senior health Key clinical sector executives appointments appointed 34% of global market Presentations to major Clinical & workflow hospital groups & research programs research institutes defined FDA regulatory approval application in process 7
Slide 8: US – key clinical appointments
US – key clinical appointments For personal use only Dr Jacque Sokolov Chair, Clinical & Scientific Advisory Boards ● Senior cardiologist & advisor to over 100 healthcare organisations ● Director, Calviri (mRNA diagnostics) ● Director, Lucid Diagnostics (DNA diagnostics – LUCID:NASDAQ) ● Previously
Slide 9: US – key clinical appointments
US – key clinical appointments For personal use only Dr Tom Cheek Dr Jim Bonnette ● Chief Medical Officer, UnitedHealthCare ● 40 years health care experience Clinical Services Continuum ● Executive Vice President, Optum Health ● Clinical VP New Markets, OptumCare ● Chief Health Officer, Cogitativo ●
Slide 10: US – full time executive team
US – full time executive team For personal use only Ted Schwab Jory Tremblay ● 35 years healthcare experience ● 35 years healthcare experience ● Previously Snr Vice President & Chief ● Previously Head of Growth, Babylon Health Innovation Officer, CHI Health ● Experience in Developed value-based and
Slide 11: US – major hospital groups, research institutes and FDA regulatory approval
US – major hospital groups, research institutes and FDA regulatory approval For personal use only Research and Payors Regulatory and Guidelines ● Discussions commenced with payors, major ● FDA hospital groups & research institutes - passed FDA ‘Refuse to Accept’ (RTA) phase, application proceeding ●
Slide 12: US – pathway to revenue
US – pathway to revenue For personal use only Sign clinical & workflow research Complete FDA agreements with major regulatory approval hospital groups mid CY22 34% of global Q4FY22 market Complete research Transition research to with major hospital revenue agreements groups Q2FY23 with hospital grou
Slide 13: UK – market entry
UK – market entry For personal use only Experienced NHS 1,250 Trust healthcare team Hospitals contracted UKCA regulatory Clinical research application program defined (audit passed Dec-21) 13
Slide 14: UK – pathway to revenue
UK – pathway to revenue For personal use only Sign workflow Commence sales & research agreement marketing with 1,250 with NHS Trust Trust Hospitals Hospital Q4FY22 Q4FY22 Complete UKCA Complete workflow regulatory approval research with Trust Q1FY23 Hospital Q2FY23 Sign first revenue agreements FY23
Slide 15: Australia – pilot market
Australia – pilot market For personal use only Admission to Expanding data Australian Therapeutic science & research Goods Register team Clinical research Growing prospective program accelerating pilot site user list 1 Incorporating pilot site learnings into product development 15
Slide 16: Australia – pathway to revenue
Australia – pathway to revenue 3 active pilots, For personal use only 4 commencing March & 36 Complete prospective Expand number of pilots incorporation of pilot SCA pilot site users site learnings into Q3FY22 product development Transition first pilot Commence pilot site site to commercial use use
Slide 17: Artrya product development progressing to schedule
Artrya product development progressing to schedule use only SCA - Salix Coronary Anatomy analysis – TGA clearance obtained SPP - Salix Procedure Planning – development to begin in 2022 SCF - Salix Coronary Flow analysis – in development SVP - Salix Vulnerable Patient – development to begin in 2022 2
Slide 18: COVID-19 Impact
COVID-19 Impact For personal use only ● No impact to date on product development but sales activity impeded ● Border closures have restricted sales and marketing travel ● Closure of medical facilities to non-essential personnel has impacted sales activity ● International travel to US and UK has been
Slide 19: Financial Summary
Financial Summary For personal use only For the six months ended 31 Dec 2021 31 Dec 2020 ($’000) ($’000) Half year results Profit & Loss Income (Other) 61 30 Expenses (6,702) (1,959) Total comprehensive loss for the period (6,641) (1, 929) Balance Sheet Cash & Cash Equivalents 43,765 12,982 Receivab
Slide 20: Summary
Summary For personal use only ● Activities proceeding to plan ● Strong cash position of $43.8m allows for planned product & market development activity ● International revenue forecast FY23 ● Current cash burn ~ $1.25m per month ● Cash burn increasing as international sales & marketing activities ex